Do analysts recommend CALT or SRZN?

Surrozen has a consensus target price of $42.00, indicating a potential upside of 70.94%. Given Surrozen's stronger consensus rating and higher probable upside, analysts plainly believe Surrozen is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Surrozen 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80

Which has higher earnings and valuation, AVLN or SRZN?

Avalyn Pharma has higher earnings, but lower revenue than Surrozen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avalyn Pharma N/A N/A N/A N/A N/A Surrozen $3.48M 81.97 -$242.03M -$37.59 N/A

Is AVLN or SRZN more profitable?

Avalyn Pharma has a net margin of 0.00% compared to Surrozen's net margin of -4,810.50%. Avalyn Pharma's return on equity of 0.00% beat Surrozen's return on equity. Company Net Margins Return on Equity Return on Assets Avalyn Pharma N/A N/A N/A Surrozen -4,810.50% -4,055.04% -154.08%

Surrozen (SRZN) Competitors

$24.57 +1.42 (+6.13%)

Closing price 06/3/2026 04:00 PM Eastern

Extended Trading

$24.63 +0.06 (+0.24%)

As of 07:38 AM Eastern

Compare

SRZN vs. CALT, OLMA, PURR, AVLN, and MRVI

Should you buy Surrozen stock or one of its competitors? MarketBeat compares Surrozen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Surrozen include Calliditas Therapeutics AB (publ) (CALT), Olema Pharmaceuticals (OLMA), Hyperliquid Strategies (PURR), Avalyn Pharma (AVLN), and Maravai LifeSciences (MRVI). These companies are all part of the "pharmaceutical products" industry.

How does Surrozen compare to Calliditas Therapeutics AB (publ)?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Surrozen (NASDAQ:SRZN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership, media sentiment and dividends.

In the previous week, Surrozen's average media sentiment score of 1.87 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Surrozen is being referred to more favorably in the news media.

Company	Overall Sentiment
Calliditas Therapeutics AB (publ)	Neutral
Surrozen	Very Positive

Calliditas Therapeutics AB (publ) has a net margin of -30.18% compared to Surrozen's net margin of -4,810.50%. Calliditas Therapeutics AB (publ)'s return on equity of -212.04% beat Surrozen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%
Surrozen	-4,810.50%	-4,055.04%	-154.08%

Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market. Comparatively, Surrozen has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market.

Surrozen has a consensus target price of $42.00, indicating a potential upside of 70.94%. Given Surrozen's stronger consensus rating and higher probable upside, analysts plainly believe Surrozen is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Surrozen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. Comparatively, 66.6% of Surrozen shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Comparatively, 31.7% of Surrozen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Surrozen. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A
Surrozen	$3.48M	81.97	-$242.03M	-$37.59	N/A

Summary

Surrozen beats Calliditas Therapeutics AB (publ) on 9 of the 16 factors compared between the two stocks.

How does Surrozen compare to Olema Pharmaceuticals?

Olema Pharmaceuticals (NASDAQ:OLMA) and Surrozen (NASDAQ:SRZN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, media sentiment, valuation, analyst recommendations and profitability.

Olema Pharmaceuticals currently has a consensus target price of $44.10, indicating a potential upside of 319.60%. Surrozen has a consensus target price of $42.00, indicating a potential upside of 70.94%. Given Olema Pharmaceuticals' higher possible upside, analysts clearly believe Olema Pharmaceuticals is more favorable than Surrozen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Surrozen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Olema Pharmaceuticals has a beta of 1.98, suggesting that its stock price is 98% more volatile than the broader market. Comparatively, Surrozen has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market.

In the previous week, Olema Pharmaceuticals had 2 more articles in the media than Surrozen. MarketBeat recorded 2 mentions for Olema Pharmaceuticals and 0 mentions for Surrozen. Surrozen's average media sentiment score of 1.87 beat Olema Pharmaceuticals' score of 0.96 indicating that Surrozen is being referred to more favorably in the news media.

Company	Overall Sentiment
Olema Pharmaceuticals	Positive
Surrozen	Very Positive

Olema Pharmaceuticals has higher earnings, but lower revenue than Surrozen. Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A
Surrozen	$3.48M	81.97	-$242.03M	-$37.59	N/A

Olema Pharmaceuticals has a net margin of 0.00% compared to Surrozen's net margin of -4,810.50%. Olema Pharmaceuticals' return on equity of -46.00% beat Surrozen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Olema Pharmaceuticals	N/A	-46.00%	-41.22%
Surrozen	-4,810.50%	-4,055.04%	-154.08%

91.8% of Olema Pharmaceuticals shares are held by institutional investors. Comparatively, 66.6% of Surrozen shares are held by institutional investors. 12.6% of Olema Pharmaceuticals shares are held by insiders. Comparatively, 31.7% of Surrozen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Olema Pharmaceuticals beats Surrozen on 10 of the 16 factors compared between the two stocks.

How does Surrozen compare to Hyperliquid Strategies?

Hyperliquid Strategies (NASDAQ:PURR) and Surrozen (NASDAQ:SRZN) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

9.5% of Hyperliquid Strategies shares are owned by institutional investors. Comparatively, 66.6% of Surrozen shares are owned by institutional investors. 8.5% of Hyperliquid Strategies shares are owned by insiders. Comparatively, 31.7% of Surrozen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Hyperliquid Strategies has a beta of 1.64, meaning that its stock price is 64% more volatile than the broader market. Comparatively, Surrozen has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market.

Hyperliquid Strategies presently has a consensus target price of $9.25, suggesting a potential downside of 10.80%. Surrozen has a consensus target price of $42.00, suggesting a potential upside of 70.94%. Given Surrozen's stronger consensus rating and higher probable upside, analysts clearly believe Surrozen is more favorable than Hyperliquid Strategies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Surrozen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Hyperliquid Strategies had 5 more articles in the media than Surrozen. MarketBeat recorded 5 mentions for Hyperliquid Strategies and 0 mentions for Surrozen. Surrozen's average media sentiment score of 1.87 beat Hyperliquid Strategies' score of 0.83 indicating that Surrozen is being referred to more favorably in the news media.

Company	Overall Sentiment
Hyperliquid Strategies	Positive
Surrozen	Very Positive

Hyperliquid Strategies has a net margin of 0.00% compared to Surrozen's net margin of -4,810.50%. Hyperliquid Strategies' return on equity of -56.04% beat Surrozen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperliquid Strategies	N/A	-56.04%	-52.22%
Surrozen	-4,810.50%	-4,055.04%	-154.08%

Hyperliquid Strategies has higher earnings, but lower revenue than Surrozen. Hyperliquid Strategies is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperliquid Strategies	$1M	1,497.95	-$16.01M	-$7.37	N/A
Surrozen	$3.48M	81.97	-$242.03M	-$37.59	N/A

Summary

Hyperliquid Strategies and Surrozen tied by winning 8 of the 16 factors compared between the two stocks.

How does Surrozen compare to Avalyn Pharma?

Avalyn Pharma (NASDAQ:AVLN) and Surrozen (NASDAQ:SRZN) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

Avalyn Pharma has a net margin of 0.00% compared to Surrozen's net margin of -4,810.50%. Avalyn Pharma's return on equity of 0.00% beat Surrozen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalyn Pharma	N/A	N/A	N/A
Surrozen	-4,810.50%	-4,055.04%	-154.08%

66.6% of Surrozen shares are owned by institutional investors. 31.7% of Surrozen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Avalyn Pharma had 5 more articles in the media than Surrozen. MarketBeat recorded 5 mentions for Avalyn Pharma and 0 mentions for Surrozen. Surrozen's average media sentiment score of 1.87 beat Avalyn Pharma's score of 0.43 indicating that Surrozen is being referred to more favorably in the news media.

Company	Overall Sentiment
Avalyn Pharma	Neutral
Surrozen	Very Positive

Avalyn Pharma currently has a consensus target price of $59.00, indicating a potential upside of 123.48%. Surrozen has a consensus target price of $42.00, indicating a potential upside of 70.94%. Given Avalyn Pharma's stronger consensus rating and higher probable upside, research analysts plainly believe Avalyn Pharma is more favorable than Surrozen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalyn Pharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.20
Surrozen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Avalyn Pharma has higher earnings, but lower revenue than Surrozen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalyn Pharma	N/A	N/A	N/A	N/A	N/A
Surrozen	$3.48M	81.97	-$242.03M	-$37.59	N/A

Summary

Avalyn Pharma beats Surrozen on 7 of the 12 factors compared between the two stocks.

How does Surrozen compare to Maravai LifeSciences?

Maravai LifeSciences (NASDAQ:MRVI) and Surrozen (NASDAQ:SRZN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.

Maravai LifeSciences has a net margin of -51.07% compared to Surrozen's net margin of -4,810.50%. Maravai LifeSciences' return on equity of -17.87% beat Surrozen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-51.07%	-17.87%	-9.08%
Surrozen	-4,810.50%	-4,055.04%	-154.08%

Maravai LifeSciences has a beta of 0.72, indicating that its stock price is 28% less volatile than the broader market. Comparatively, Surrozen has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market.

Maravai LifeSciences has higher revenue and earnings than Surrozen. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$185.74M	6.73	-$130.77M	-$0.71	N/A
Surrozen	$3.48M	81.97	-$242.03M	-$37.59	N/A

Maravai LifeSciences currently has a consensus price target of $5.50, indicating a potential upside of 13.64%. Surrozen has a consensus price target of $42.00, indicating a potential upside of 70.94%. Given Surrozen's stronger consensus rating and higher possible upside, analysts clearly believe Surrozen is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Surrozen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

50.3% of Maravai LifeSciences shares are held by institutional investors. Comparatively, 66.6% of Surrozen shares are held by institutional investors. 2.5% of Maravai LifeSciences shares are held by insiders. Comparatively, 31.7% of Surrozen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Maravai LifeSciences had 2 more articles in the media than Surrozen. MarketBeat recorded 2 mentions for Maravai LifeSciences and 0 mentions for Surrozen. Surrozen's average media sentiment score of 1.87 beat Maravai LifeSciences' score of 0.82 indicating that Surrozen is being referred to more favorably in the news media.

Company	Overall Sentiment
Maravai LifeSciences	Positive
Surrozen	Very Positive

Summary

Maravai LifeSciences and Surrozen tied by winning 8 of the 16 factors compared between the two stocks.

Get Surrozen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SRZN vs. The Competition

Export

Metric	Surrozen	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$268.72M	$2.93B	$6.47B	$12.54B
Dividend Yield	N/A	1.68%	2.69%	5.22%
P/E Ratio	-0.65	17.69	22.12	24.18
Price / Sales	81.97	302.27	524.88	112.26
Price / Cash	N/A	55.72	41.34	57.13
Price / Book	-1.28	3.85	9.95	6.72
Net Income	-$242.03M	$75.85M	$3.57B	$337.19M
7 Day Performance	-6.08%	-3.99%	-2.46%	-0.75%
1 Month Performance	N/A	N/A	N/A	-1.69%
1 Year Performance	195.67%	19.65%	26.57%	33.09%

Surrozen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SRZN Surrozen	4.0003 of 5 stars	$24.57 +6.1%	$42.00 +70.9%	+192.5%	$268.72M	$3.48M	N/A	80
CALT Calliditas Therapeutics AB (publ)	N/A	$40.00 flat	N/A	N/A	$1.19B	$1.60B	N/A	180
OLMA Olema Pharmaceuticals	3.1975 of 5 stars	$13.54 -0.1%	$44.10 +225.8%	+159.5%	$1.18B	N/A	N/A	70
PURR Hyperliquid Strategies	1.4787 of 5 stars	$8.54 +1.0%	$9.25 +8.4%	N/A	$1.15B	$1M	N/A	N/A
AVLN Avalyn Pharma	4.8589 of 5 stars	$27.20 +1.9%	$59.00 +116.9%	N/A	$1.14B	N/A	N/A	51	News Coverage Earnings Report Short Interest Increase Quiet Period Expiration

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SRZN) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Surrozen (SRZN) Competitors

SRZN vs. CALT, OLMA, PURR, AVLN, and MRVI

How does Surrozen compare to Calliditas Therapeutics AB (publ)?

Summary

How does Surrozen compare to Olema Pharmaceuticals?

Summary

How does Surrozen compare to Hyperliquid Strategies?

Summary

How does Surrozen compare to Avalyn Pharma?

Summary

How does Surrozen compare to Maravai LifeSciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRZN vs. The Competition

Surrozen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Surrozen (SRZN) Competitors

SRZN vs. CALT, OLMA, PURR, AVLN, and MRVI

How does Surrozen compare to Calliditas Therapeutics AB (publ)?

Does the media favor CALT or SRZN?

Is CALT or SRZN more profitable?

Which has more risk and volatility, CALT or SRZN?

Do analysts recommend CALT or SRZN?

Do insiders & institutionals have more ownership in CALT or SRZN?

Which has better valuation & earnings, CALT or SRZN?

Summary

How does Surrozen compare to Olema Pharmaceuticals?

Do analysts rate OLMA or SRZN?

Which has more volatility and risk, OLMA or SRZN?

Does the media prefer OLMA or SRZN?

Which has higher valuation & earnings, OLMA or SRZN?

Is OLMA or SRZN more profitable?

Do insiders & institutionals have more ownership in OLMA or SRZN?

Summary

How does Surrozen compare to Hyperliquid Strategies?

Do institutionals and insiders hold more shares of PURR or SRZN?

Which has more risk & volatility, PURR or SRZN?

Do analysts recommend PURR or SRZN?

Does the media favor PURR or SRZN?

Is PURR or SRZN more profitable?

Which has higher valuation and earnings, PURR or SRZN?

Summary

How does Surrozen compare to Avalyn Pharma?

Is AVLN or SRZN more profitable?

Do insiders & institutionals believe in AVLN or SRZN?

Does the media refer more to AVLN or SRZN?

Do analysts recommend AVLN or SRZN?

Which has higher earnings and valuation, AVLN or SRZN?

Summary

How does Surrozen compare to Maravai LifeSciences?

Is MRVI or SRZN more profitable?

Which has more volatility & risk, MRVI or SRZN?

Which has stronger earnings and valuation, MRVI or SRZN?

Do analysts rate MRVI or SRZN?

Do institutionals and insiders believe in MRVI or SRZN?

Does the media favor MRVI or SRZN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRZN vs. The Competition

Surrozen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools